ArticleMolecular nutrition & food research2026
Phagocytosis of Primary Human Macrophages is Elevated by Ex Vivo Supplementation with n-3 PUFA.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Epidemiologic studies show that a high n-3 polyunsaturated fatty acid (PUFA) status is beneficial for health and inflammatory diseases. However, results of nutrition studies investigating the impact of n-3 PUFA intake on immune functions, such as phagocytosis are contradictory. In order to gain more insights into the role of n-3 PUFAs on phagocytosis, we investigated the modulation of phagocytosis by n-3 PUFAs and derived oxylipins in human macrophages. Using an established ex vivo supplementation strategy, primary human macrophages were supplemented with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). The PUFA pattern of the cells was shifted from a low n-3 PUFA status towards a high n-3 PUFA status. This was accompanied by a shift in the oxylipin pattern, reduced pro-inflammatory prostaglandin levels, increased phagocytosis in the supplemented macrophages, and reduced inhibitory effect of PGE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.